Next Generation Sequencing MarketSize, Share & Industry Analysis, 2026-2034By ProductBy TechnologyBy ApplicationBy WorkflowBy End User
Full title & scope — all 5 axes with their segments
Next Generation Sequencing Market Size, Share & Industry Analysis, By Product (Consumables, Platforms, Data Analysis, Sample preparation, Target Enrichment, Others), By Technology (WGS, Whole Exome Sequencing, DNA-based, RNA-based), By Application (Oncology, Diagnostics and Screening, Oncology Screening, Sporadic Cancer, Inherited Cancer, Companion Diagnostics, Other Diagnostics, Clinical Investigation, Infectious Diseases, Inherited Diseases, Idiopathic Diseases, Non-communicable/Other Diseases, NIPT, Aneuploidy, Microdeletions, PGT, Newborn Genetic Screening, Single Gene Analysis, HLA Typing/Immune System Monitoring, Metagenomics, Epidemiology & Drug Development, Agrigenomics & Forensics, Consumer Genomics), By Workflow (NGS Library Preparation Kits, Semi-automated Library Preparation, Automated Library Preparation, Clonal Amplification, NGS Data Analysis, NGS Primary Data Analysis, NGS Secondary Data Analysis, NGS Tertiary Data Analysis), By End User (Academic & Research Institutes, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others), and Regional Forecast, 2026-2034
Full table of contents for the published report, chapter by chapter.
- 01By ProductConsumables · Platforms · Data Analysis
- 02By TechnologyWGS · Whole Exome Sequencing · DNA-based
- 03By ApplicationOncology · Diagnostics and Screening · Oncology Screening
- 04By WorkflowNGS Library Preparation Kits · Semi-automated Library Preparation · Automated Library Preparation
- 05By End UserAcademic & Research Institutes · Hospitals & Clinics · Pharmaceutical & Biotechnology Companies
- 06By Region
Market Analysis & Outlook
Next generation sequencing covers the instruments, reagent kits, consumables and data analysis software and services used to determine the order of nucleotides in DNA and RNA at high throughput, replacing the slower single-target sequencing methods used previously. It spans whole genome and whole exome sequencing platforms, the library preparation and target enrichment kits that prepare samples for a sequencing run, and the primary, secondary and tertiary bioinformatics software that turns raw sequencing reads into a usable result. Buyers include academic and hospital genomics laboratories, pharmaceutical and biotechnology companies running drug discovery and companion diagnostics programs, and public health and reproductive health screening programs.
Between 2025 and 2034 the global next generation sequencing market moves from USD 14.51 billion to USD 49.09 billion, compounding at 14.5% a year. Fifteen years are covered in all, taking in USD 6.34 billion in 2020, USD 12.3 billion in 2024, USD 16.61 billion in 2026 and USD 28.56 billion in 2030.
Composition changes more than the total does. Data Analysis, at 20.26%, outgrows Platforms at 11.96%, and its share moves from 13.99% to 22%. Consumables stays the largest line throughout, at USD 5.51 billion in 2025 and USD 16.69 billion in 2034. Share moves toward Data Analysis and Sample preparation and away from Consumables, Platforms, Target Enrichment and Others, though no line shrinks in revenue terms.
The technology split puts WGS first, at USD 4.35 billion and 29.98% of revenue in 2025, rising to USD 17.67 billion and 36% in 2034. It is also the fastest-growing line on this axis at 16.86%, so the split concentrates rather than balances over the period. It cuts the same total as the product axis from a different commercial angle, so revenue does not add across the two.
USD 6.09 billion of 2025 revenue is generated in North America, 41.97% of the global total and the largest regional share; it reaches USD 18.66 billion by 2034. Europe is next at 25.98% and USD 3.77 billion, and Middle East and Africa last at 5.03%. Asia Pacific and Latin America gain share across the period, so growth is not distributed evenly between regions.
Coverage extends to five regions, six product lines and five segmentation axes over the full fifteen years. The 2025 total itself is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- The global next generation sequencing market moves from USD 6.34 billion in 2020 to USD 14.51 billion in 2025 and USD 49.09 billion by 2034, the forecast period compounding at 14.5% a year.
- The largest line by product is Consumables, worth USD 5.51 billion and 37.97% of revenue in 2025, rising to USD 16.69 billion and 34% by 2034.
- Fastest growth on the product axis belongs to Data Analysis: 20.26% a year, USD 2.03 billion to USD 10.8 billion, and a share moving from 13.99% to 22%.
- Against a base case of USD 49.09 billion in 2034, the study also reports a bear case at USD 42.71 billion and a bull case at USD 56.45 billion, with the assumptions behind each set out separately.
- North America holds 41.97% of global revenue in 2025 at USD 6.09 billion, the largest of the five regions tracked, and reaches USD 18.66 billion by 2034.
- The United States accounts for 85.06% of North America in the base year, worth USD 5.18 billion in 2025 and reaching USD 15.86 billion by 2034, the worked country example carried through that region's chapters.
- The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.
Market Trends
Revenue Share, By By Product
Base year 2025Consumables leads with 38.0% of by product segment revenue.
Share of by product segment revenue, most recent base year.
Three movements define the forecast period in the global next generation sequencing market: how the product mix changes, where regional weight shifts, and the rate at which the total compounds.
None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; what changes is which of them captures the revenue added.
The product mix tilts toward Data Analysis. Data Analysis grows at 20.26% across 2026-2034 against 11.96% for Platforms, the widest spread on the product axis. Data Analysis takes its share of revenue from 13.99% to 22% while Platforms gives up ground, from 21.98% to 18.01%. In absolute terms Data Analysis rises from USD 2.03 billion to USD 10.8 billion, while Platforms rises from USD 3.19 billion to USD 8.84 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.
The regional balance moves. Asia Pacific moves from 21.99% of revenue in 2025 to 26.99% in 2034, worth USD 3.19 billion rising to USD 13.25 billion; Latin America moves from 5.03% of revenue in 2025 to 6.01% in 2034, worth USD 0.73 billion rising to USD 2.95 billion. The offsetting side is North America at 41.97% moving to 38.01%, Europe at 25.98% moving to 24%, Middle East and Africa at 5.03% moving to 4.99%, none of which contracts. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.
Growth compounds at 14.5% without a step change. The market moves through USD 6.34 billion in 2020, USD 12.3 billion in 2024, USD 14.51 billion in 2025, USD 16.61 billion in 2026, USD 28.56 billion in 2030 and USD 49.09 billion in 2034. The forecast rate of 14.5% sits against 18.01% over the historical period, so the projection extends an observed trend instead of proposing a new one. That moves the planning question away from timing a turn and onto the product and regional mixes, where the actual movement is.
Market Growth Factors
The fastest line decides the blended rate
Market Drivers
3- 01The fastest line decides the blended rate
20.26% growth in Data Analysis, against 14.5% for the market as a whole, moves it from USD 2.03 billion and 13.99% of revenue in 2025 to USD 10.8 billion and 22% in 2034. Set against 11.96% at the other end of the axis, this is the line that decides whether the market's 14.5% holds. That makes position on the product axis a growth decision rather than a product one.
- 02Regional weight, not regional count
The largest regional base is North America: USD 6.09 billion in 2025 at 41.97% of the global total, USD 18.66 billion by 2034, still 38.01%. Europe is next at 25.98% of revenue, USD 3.77 billion in 2025 and USD 11.78 billion in 2034. Together the two account for the majority of both the 2025 base and the revenue added by 2034, which is why a regional plan treating all five regions at equal weight misreads where the growth actually lands.
- 03Fifteen years of unbroken growth underpin the forecast
Revenue rose through USD 6.34 billion in 2020, USD 12.3 billion in 2024 and USD 14.51 billion in 2025, a compound 18.01% across the historical period. From there the forecast carries 14.5% through to USD 49.09 billion in 2034. With the trajectory already demonstrated over fifteen years, what remains uncertain is the mix rather than the direction, which is where the segment and regional sections do the work.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Declining per-sample sequencing cost accelerating clinical adoption | High | +12.5 | High | High | Medium |
| 2 | Expansion of oncology companion diagnostics and liquid biopsy programs | High | +8.8 | Medium | High | High |
| 3 | Growth in reproductive health screening volumes | Medium-High | +6.2 | Medium | High | High |
| 4 | Government and public health genomics initiatives | Medium | +5.1 | Medium | Medium | Medium |
| 5 | Rising pharmaceutical R&D and drug discovery sequencing demand | Medium | +4.3 | Medium | Medium | Low |
| 6 | Others | Low | +1.68 | Low | Low | Low |
| Total | +38.58 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | High capital and reagent costs limiting adoption in price-sensitive settings | Medium | −1.8 | High | Medium | Low |
| 2 | Data infrastructure and bioinformatics talent shortages | Medium | −1.3 | Medium | Medium | Medium |
| 3 | Reimbursement and regulatory heterogeneity across markets | Low | −0.9 | Medium | Low | Low |
| Total | −4 | |||||
Drivers contribute 38.58 Billion and restraints remove 4 Billion, a net 34.58 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 14.5% into its parts and three show up: an already-large base compounding, the product mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
The bear case and what drives it
Market Restraints
2- 01The bear case and what drives it
Reagent and consumables pricing stays firmer than expected and reimbursement expansion for companion diagnostics and NIPT slows in major markets, delaying the shift from research to routine clinical use. On that assumption 2034 revenue lands at USD 42.71 billion rather than the USD 49.09 billion base case, from the same USD 14.51 billion 2025 starting point.
- 02The largest line is not the fastest
Consumables carries 37.97% of 2025 revenue at USD 5.51 billion but compounds at 13.06% against 14.5% for the market, taking its share to 34% by 2034 even as revenue rises to USD 16.69 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Where the forecast could be beaten
Market Opportunities
2- 01Where the forecast could be beaten
The upside path assumes sequencing reagent costs fall faster than the base case and companion diagnostics reimbursement expands into more markets sooner, pulling forward clinical adoption. It ends 2034 at USD 56.45 billion against a USD 49.09 billion base case, off the same USD 14.51 billion base year.
- 02Data Analysis share moves from 13.99% to 22%
Share on the product axis moves toward Data Analysis, from 13.99% in 2025 to 22% in 2034, on 20.26% growth against the market's 14.5% and revenue rising from USD 2.03 billion to USD 10.8 billion. Taking position there does not require displacing whoever holds Consumables, which is the harder and more expensive fight.
Market Challenges
One product line carries the market
Market Challenges
2- 01One product line carries the market
One line dominates: Consumables, at 37.97% of revenue in 2025 and 34% in 2034, worth USD 5.51 billion and USD 16.69 billion. No other single change on the product axis moves the total as much as a change in demand for that one line.
- 02The United States is 85.06% of North America
Of North America's USD 6.09 billion in 2025, USD 5.18 billion (85.06%) comes from the United States alone, rising to USD 15.86 billion by 2034. The consequence is that regional risk here is really country risk wearing a larger label.
Segmentation Analysis
5 axesThe market is divided by product and by technology, application, workflow and end user; five axes in all. They are alternative readings of one revenue pool, not parts that sum to it.
All six product lines expand in revenue terms over the forecast period. Share is the dividing line; two take it, the others cede it.
By Product · 6 segments
Data Analysis Outpaces the Axis While Consumables Holds the Largest Share
- Largest Consumables · 38%
- Fastest Data Analysis · 20.3%
- Moves most Data Analysis · +8 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Consumables | $5.51B | 38% | $16.69B | 34%-4 | 13.1% |
| Platforms | $3.19B | 22% | $8.84B | 18%-4 | 12% |
| Data Analysis | $2.03B | 14% | $10.80B | 22%+8 | 20.3% |
| Sample preparation | $1.74B | 12% | $5.89B | 12% | 14.5% |
| Target Enrichment | $1.31B | 9% | $4.42B | 9% | 14.6% |
| Others | $0.73B | 5% | $2.45B | 5% | 14.5% |
Consumables leads because sequencing is a recurring reagent business: every run consumes new library preparation and sequencing kits regardless of instrument age, while platform sales are a one time capital purchase. Data analysis grows fastest as laboratories accumulate archived sequencing data and shift spending toward interpretation and storage rather than adding further instrument capacity. The order does not change: Consumables is still largest in 2034, and what moves is how much it holds. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Technology · 4 segments
WGS Holds the Largest Technology Share and Is Still the Quickest to Grow
- Largest WGS · 30%
- Fastest WGS · 16.9%
- Moves most WGS · +6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| WGS | $4.35B | 30% | $17.67B | 36%+6 | 16.9% |
| Whole Exome Sequencing | $3.19B | 22% | $10.31B | 21%-1 | 13.9% |
| DNA-based | $4.07B | 28.1% | $11.29B | 23%-5.1 | 12% |
| RNA-based | $2.90B | 20% | $9.82B | 20% | 14.5% |
Whole genome sequencing leads because it captures the full genome in a single run, which laboratories increasingly prefer over ordering multiple targeted panels separately. It is also the fastest growing category, since falling per run costs are making full genome runs affordable for applications that previously defaulted to exome or targeted panels to control cost. By 2034 WGS is still ahead, making this a shift in weight rather than a change of leader.
By Application · 23 segments
By Application
- Largest Oncology · 16.6%
- Fastest Newborn Genetic Screening · 19.8%
- Moves most Oncology · -3.5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Oncology | $2.41B | 16.6% | $6.42B | 13.1%-3.5 | 11.5% |
| Diagnostics and Screening | $1.02B | 7% | $2.95B | 6%-1 | 12.5% |
| Oncology Screening | $0.73B | 5% | $2.45B | 5% | 14.4% |
| Sporadic Cancer | $0.58B | 4% | $1.96B | 4% | 14.5% |
| Inherited Cancer | $0.44B | 3% | $1.47B | 3% | 14.3% |
| Companion Diagnostics | $0.73B | 5% | $2.95B | 6%+1 | 16.8% |
| Other Diagnostics | $0.44B | 3% | $1.47B | 3% | 14.3% |
| Clinical Investigation | $0.58B | 4% | $1.47B | 3%-1 | 10.9% |
| Infectious Diseases | $1.60B | 11% | $3.93B | 8%-3 | 10.5% |
| Inherited Diseases | $0.73B | 5% | $2.45B | 5% | 14.4% |
| Idiopathic Diseases | $0.44B | 3% | $1.47B | 3% | 14.3% |
| Non-communicable/Other Diseases | $0.44B | 3% | $1.47B | 3% | 14.3% |
| NIPT | $0.87B | 6% | $3.93B | 8%+2 | 18.3% |
| Aneuploidy | $0.44B | 3% | $1.96B | 4%+1 | 18.1% |
| Microdeletions | $0.29B | 2% | $0.98B | 2% | 14.5% |
| PGT | $0.44B | 3% | $1.96B | 4%+1 | 18.1% |
| Newborn Genetic Screening | $0.29B | 2% | $1.47B | 3%+1 | 19.8% |
| Single Gene Analysis | $0.44B | 3% | $1.47B | 3% | 14.3% |
| HLA Typing/Immune System Monitoring | $0.29B | 2% | $0.98B | 2% | 14.5% |
| Metagenomics | $0.29B | 2% | $1.47B | 3%+1 | 19.8% |
| Epidemiology & Drug Development | $0.44B | 3% | $1.96B | 4%+1 | 18.1% |
| Agrigenomics & Forensics | $0.29B | 2% | $0.98B | 2% | 14.5% |
| Consumer Genomics | $0.29B | 2% | $1.47B | 3%+1 | 19.8% |
2025 to 2034 revenue and share by line: Oncology USD 2.41 billion to USD 6.42 billion (16.61% in 2025), Infectious Diseases USD 1.6 billion to USD 3.93 billion (11.03% in 2025), Diagnostics and Screening USD 1.02 billion to USD 2.95 billion (7.03% in 2025), NIPT USD 0.87 billion to USD 3.93 billion (6% in 2025), Oncology Screening USD 0.73 billion to USD 2.45 billion (5.03% in 2025), Companion Diagnostics USD 0.73 billion to USD 2.95 billion (5.03% in 2025), Inherited Diseases USD 0.73 billion to USD 2.45 billion (5.03% in 2025), Sporadic Cancer USD 0.58 billion to USD 1.96 billion (4% in 2025), Clinical Investigation USD 0.58 billion to USD 1.47 billion (4% in 2025), Inherited Cancer USD 0.44 billion to USD 1.47 billion (3.03% in 2025), Other Diagnostics USD 0.44 billion to USD 1.47 billion (3.03% in 2025), Idiopathic Diseases USD 0.44 billion to USD 1.47 billion (3.03% in 2025), Non-communicable/Other Diseases USD 0.44 billion to USD 1.47 billion (3.03% in 2025), Aneuploidy USD 0.44 billion to USD 1.96 billion (3.03% in 2025), PGT USD 0.44 billion to USD 1.96 billion (3.03% in 2025), Single Gene Analysis USD 0.44 billion to USD 1.47 billion (3.03% in 2025), Epidemiology & Drug Development USD 0.44 billion to USD 1.96 billion (3.03% in 2025), Microdeletions USD 0.29 billion to USD 0.98 billion (2% in 2025), Newborn Genetic Screening USD 0.29 billion to USD 1.47 billion (2% in 2025), HLA Typing/Immune System Monitoring USD 0.29 billion to USD 0.98 billion (2% in 2025), Metagenomics USD 0.29 billion to USD 1.47 billion (2% in 2025), Agrigenomics & Forensics USD 0.29 billion to USD 0.98 billion (2% in 2025), Consumer Genomics USD 0.29 billion to USD 1.47 billion (2% in 2025). Newborn Genetic Screening Outpaces the Axis While Oncology Holds the Largest Share Oncology leads because cancer testing already has established clinical pathways and reimbursement precedent that newer application areas are still building. Reproductive health categories such as NIPT and prenatal screening grow fastest as non invasive testing keeps replacing older invasive procedures, and consumer genomics grows quickly off a small base as direct to consumer testing broadens beyond ancestry. Oncology remains the largest line through 2034, so the axis changes in proportion rather than in order.
By Workflow · 8 segments
By Workflow
- Largest NGS Library Preparation Kits · 20%
- Fastest Automated Library Preparation · 18.9%
- Moves most NGS Library Preparation Kits · -4 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| NGS Library Preparation Kits | $2.90B | 20% | $7.85B | 16%-4 | 11.7% |
| Semi-automated Library Preparation | $1.74B | 12% | $4.91B | 10%-2 | 12.2% |
| Automated Library Preparation | $1.45B | 10% | $6.87B | 14%+4 | 18.9% |
| Clonal Amplification | $2.18B | 15% | $6.38B | 13%-2 | 12.7% |
| NGS Data Analysis | $2.61B | 18% | $9.82B | 20%+2 | 15.9% |
| NGS Primary Data Analysis | $1.45B | 10% | $4.42B | 9%-1 | 13.2% |
| NGS Secondary Data Analysis | $1.31B | 9% | $4.91B | 10%+1 | 15.8% |
| NGS Tertiary Data Analysis | $0.87B | 6% | $3.93B | 8%+2 | 18.3% |
2025 to 2034 revenue and share by line: NGS Library Preparation Kits USD 2.9 billion to USD 7.85 billion (19.99% to 15.99%), NGS Data Analysis USD 2.61 billion to USD 9.82 billion (17.99% to 20%), Clonal Amplification USD 2.18 billion to USD 6.38 billion (15.02% to 13%), Semi-automated Library Preparation USD 1.74 billion to USD 4.91 billion (11.99% to 10%), Automated Library Preparation USD 1.45 billion to USD 6.87 billion (9.99% to 13.99%), NGS Primary Data Analysis USD 1.45 billion to USD 4.42 billion (9.99% to 9%), NGS Secondary Data Analysis USD 1.31 billion to USD 4.91 billion (9.03% to 10%), NGS Tertiary Data Analysis USD 0.87 billion to USD 3.93 billion (6% to 8.01%). NGS Library Preparation Kits Held the Dominant Share of the Workflow Segment in 2025 Library preparation kits lead because every sequencing run, regardless of platform or application, requires a prepared library first, making it the workflow step with the broadest addressable base. Automated library preparation grows fastest as laboratories processing higher sample volumes replace manual and semi automated handling to cut turnaround time and reduce operator to operator variability. By 2034 the largest line is NGS Data Analysis rather than NGS Library Preparation Kits, the one axis here where the order actually changes.
By End User · 4 segments
Hospitals & Clinics Outpaces the Axis While Academic & Research Institutes Holds the Largest Share
- Largest Academic & Research Institutes · 35%
- Fastest Hospitals & Clinics · 16.1%
- Moves most Academic & Research Institutes · -5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Academic & Research Institutes | $5.08B | 35% | $14.73B | 30%-5 | 12.6% |
| Hospitals & Clinics | $3.19B | 22% | $12.27B | 25%+3 | 16.1% |
| Pharmaceutical & Biotechnology Companies | $4.79B | 33% | $18.16B | 37%+4 | 16% |
| Others | $1.45B | 10% | $3.93B | 8%-2 | 11.7% |
Academic and research institutes lead because sequencing adoption has historically concentrated in research settings before moving into clinical and commercial use. Pharmaceutical and biotechnology companies grow fastest as sequencing becomes a standard tool in drug discovery and companion diagnostics development, shifting more of the buyer base toward commercial rather than purely academic demand. Leadership changes hands: Pharmaceutical & Biotechnology Companies is the largest line by 2034, not Academic & Research Institutes.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 4 points of share move elsewhere by 2034, while revenue still grows 3.1×.
- Rank 1 of 5
- 2025 share 42%
- By 2034 38%
- Revenue $6.09B → $18.66B
North America holds 41.97% of the global next generation sequencing market in 2025, worth USD 6.09 billion and reaches USD 18.66 billion by 2034. That makes it the first-largest region covered, in 2025 and again in 2034.
By 2034 the share stands at 38.01%, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.
Segment composition follows the global pattern: Consumables largest at 37.97% of 2025 revenue, Data Analysis fastest at 20.26%. North America is reported axis by axis and country by country in the full study.
United States
Sets the pace for North America at 85.1% of it, growing 3.1×.
- In region 1 of 2
- Of region 85.1%
- Of global 35.7%
- Revenue $5.18B → $15.86B
USD 5.18 billion of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 15.86 billion by 2034. At 85.06% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Regional revenue of USD 6.09 billion in 2025 and USD 18.66 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
the United States buys along the same lines as the market globally; Consumables first at 37.97% of 2025 revenue and 34% in 2034, Data Analysis fastest at 20.26% on a share moving from 13.99% to 22%. Since 85.06% of North America's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. The United States carries its own product breakdown in the full report.
In the United States, next generation sequencing platforms and reagent kits intended for clinical diagnostic use fall under the Food and Drug Administration's in vitro diagnostic device framework, requiring either premarket approval or De Novo classification depending on the claims made and the risk associated with the intended use. Many laboratories instead offer sequencing-based assays as laboratory-developed tests, which are run under Clinical Laboratory Improvement Amendments certification and overseen by the Centers for Medicare and Medicaid Services rather than through device clearance. Instruments and reagents sold strictly for research use must be labelled accordingly, restricting the manufacturer from making diagnostic claims, and any move toward clinical marketing requires a formal submission demonstrating analytical and clinical validity.
Competition in the United States runs between the suppliers this study tracks: Illumina, F. Hoffman-La Roche Ltd., QIAGEN, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies, PierianDx, Genomatix GmbH, DNASTAR, Inc., Perkin Elmer, Inc., Eurofins GATC Biotech GmbH, BGI, Agilent Technologies, Inc., Pacific Biosciences of California, Inc. and Twist Bioscience Corporation. The commercially relevant division is 37.97% of 2025 revenue in Consumables, where the volume is, against 20.26% growth in Data Analysis, where share moves. Per-company positioning and share at country level are in the full report only.
Canada
2nd-largest in North America, growing 3.1×.
- In region 2 of 2
- Of region 14.9%
- Of global 6.3%
- Revenue $0.91B → $2.80B
Within North America, Canada accounts for 14.94% of regional revenue and 6.27% of the global total, worth USD 0.91 billion in 2025 and USD 2.8 billion by 2034.
Europe Market Analysis
The 2nd-largest region covered — 2 points of share move elsewhere by 2034, while revenue still grows 3.1×.
- Rank 2 of 5
- 2025 share 26%
- By 2034 24%
- Revenue $3.77B → $11.78B
25.98% of the global next generation sequencing market sits in Europe in 2025, worth USD 3.77 billion and reaches USD 11.78 billion by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.
Share settles at 24% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Consumables leads here as it does globally, at 37.97% of 2025 revenue, and Data Analysis again grows fastest at 20.26%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.
Germany
The largest market in Europe, growing 3.1×.
- In region 1 of 3
- Of region 30%
- Of global 7.8%
- Revenue $1.13B → $3.53B
USD 1.13 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 3.53 billion by 2034. Its 29.97% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Set against USD 3.77 billion and USD 11.78 billion for the region, it is why this market rather than a smaller one is the one reported in full.
Demand in Germany follows the product mix reported at global level: Consumables is the largest line at 37.97% of 2025 revenue, moving to 34% by 2034, while Data Analysis grows fastest at 20.26% and takes its share from 13.99% to 22%. Because the country carries 29.97% of Europe, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The full report reports Germany by product separately.
In Germany, next generation sequencing systems marketed for clinical or diagnostic purposes are governed by the EU In Vitro Diagnostic Regulation, which replaced the earlier directive-based regime and requires manufacturers to classify their product according to risk, compile technical documentation, and in most cases involve a notified body before affixing the CE mark. The Federal Institute for Drugs and Medical Devices acts as the competent national authority, receiving vigilance reports and overseeing market surveillance once a product is placed on the market. Suppliers must also maintain a certified quality management system and appoint a person responsible for regulatory compliance, while software used to interpret sequencing output is assessed under the same regulation if it drives a diagnostic conclusion.
The suppliers tracked in this study (Illumina, F. Hoffman-La Roche Ltd., QIAGEN, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies, PierianDx, Genomatix GmbH, DNASTAR, Inc., Perkin Elmer, Inc., Eurofins GATC Biotech GmbH, BGI, Agilent Technologies, Inc., Pacific Biosciences of California, Inc. and Twist Bioscience Corporation) compete in Germany across the product lines above. Volume sits in Consumables at 37.97% of 2025 revenue; movement sits in Data Analysis at 20.26% growth.
United Kingdom
2nd-largest in Europe, growing 3.1×.
- In region 2 of 3
- Of region 24.9%
- Of global 6.5%
- Revenue $0.94B → $2.95B
The United Kingdom is sized at USD 0.94 billion in 2025, rising to USD 2.95 billion by 2034; 6.48% of global revenue and 24.93% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
France
3rd-largest in Europe, growing 3.1×.
- In region 3 of 3
- Of region 19.9%
- Of global 5.2%
- Revenue $0.75B → $2.36B
5.17% of global revenue is generated in France; USD 0.75 billion in 2025, reaching USD 2.36 billion in 2034, and 19.89% of Europe.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 5 points of share by 2034, while revenue still grows 4.2×.
- Rank 3 of 5
- 2025 share 22%
- By 2034 27%
- Revenue $3.19B → $13.25B
USD 3.19 billion of 2025 revenue is generated in Asia Pacific, 21.99% of the global next generation sequencing market with USD 13.25 billion projected for 2034. Among the five regions it ranks third by revenue in both years.
Share climbs to 26.99% by 2034, at a pace above the 14.5% global rate, which is what makes this region worth reading separately rather than scaling from the total.
The product mix reported at global level applies here, with Consumables the largest line at 37.97% of 2025 revenue and Data Analysis the fastest-growing at 20.26%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.
China
The largest market in Asia Pacific, growing 4.1×.
- In region 1 of 3
- Of region 40.1%
- Of global 8.8%
- Revenue $1.28B → $5.30B
40.13% of Asia Pacific's base-year revenue comes from China; USD 1.28 billion, rising to USD 5.3 billion by 2034. At 40.13% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Against regional totals of USD 3.19 billion in 2025 and USD 13.25 billion in 2034, it is the country the full report breaks out in detail.
Demand in China follows the product mix reported at global level: Consumables is the largest line at 37.97% of 2025 revenue, moving to 34% by 2034, while Data Analysis grows fastest at 20.26% and takes its share from 13.99% to 22%. Because the country carries 40.13% of Asia Pacific, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Per-product revenue for China appears on its own in the full report.
In China, next generation sequencing instruments and reagent kits intended for diagnostic use are regulated by the National Medical Products Administration as in vitro diagnostic medical devices, with the applicable pathway determined by the risk classification assigned to the product. Higher-risk sequencing-based assays generally require registration review including clinical evaluation data generated within the country, while lower-risk components may follow a simpler filing route. Imported systems require a local agent and must conform to national standards covering performance and labelling before sale is permitted. Laboratories offering sequencing services under a laboratory-developed test model operate under separate health-authority oversight distinct from the device registration route.
Illumina, F. Hoffman-La Roche Ltd., QIAGEN, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies, PierianDx, Genomatix GmbH, DNASTAR, Inc., Perkin Elmer, Inc., Eurofins GATC Biotech GmbH, BGI, Agilent Technologies, Inc., Pacific Biosciences of California, Inc. and Twist Bioscience Corporation are the suppliers covered in China. The commercially relevant division is 37.97% of 2025 revenue in Consumables, where the volume is, against 20.26% growth in Data Analysis, where share moves.
Japan
2nd-largest in Asia Pacific, growing 4.1×.
- In region 2 of 3
- Of region 30.1%
- Of global 6.6%
- Revenue $0.96B → $3.98B
Japan is sized at USD 0.96 billion in 2025, rising to USD 3.98 billion by 2034; 6.62% of global revenue and 30.09% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
India
3rd-largest in Asia Pacific, growing 4.1×.
- In region 3 of 3
- Of region 15.1%
- Of global 3.3%
- Revenue $0.48B → $1.99B
Within Asia Pacific, India accounts for 15.05% of regional revenue and 3.31% of the global total, worth USD 0.48 billion in 2025 and USD 1.99 billion by 2034.
Latin America Market Analysis
The 4th-largest region covered — it picks up 1 point of share by 2034, while revenue still grows 4.0×.
- Rank 4 of 5
- 2025 share 5%
- By 2034 6%
- Revenue $0.73B → $2.95B
In Latin America, 5.03% of global revenue puts 2025 at USD 0.73 billion and reaches USD 2.95 billion by 2034. Among the five regions it ranks fourth by revenue in both years.
By 2034 the share has moved up to 6.01%, so the region grows faster than the market's 14.5% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
Within the region the product split tracks the global one; 37.97% of 2025 revenue in Consumables, fastest growth of 20.26% in Data Analysis. Latin America is reported axis by axis and country by country in the full study.
Brazil
The largest market in Latin America, growing 4.0×.
- In region 1 of 2
- Of region 54.8%
- Of global 2.8%
- Revenue $0.40B → $1.62B
The largest single market in Latin America is Brazil, at USD 0.4 billion in 2025 and USD 1.62 billion in 2034. 54.79% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 0.73 billion in 2025 and USD 2.95 billion in 2034, it is the country the full report breaks out in detail.
The product pattern in Brazil is the global one: 37.97% of 2025 revenue in Consumables, 34% by 2034, against 20.26% growth in Data Analysis taking it from 13.99% to 22%. With 54.79% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-product revenue for Brazil appears on its own in the full report.
In Brazil, next generation sequencing platforms and diagnostic reagent kits are regulated by Agência Nacional de Vigilância Sanitária, which classifies in vitro diagnostic products by risk and requires product registration before commercialisation, supported by a technical dossier demonstrating safety and performance. Manufacturers must hold or work through a local registration holder, comply with Brazilian good manufacturing practice requirements verified through facility inspection, and ensure labelling and instructions for use are presented in Portuguese. Post-market obligations include adverse-event reporting and participation in the national vigilance system, and any change to an approved sequencing kit's composition or intended use typically triggers a fresh review before the updated version may be sold.
In Brazil the field is Illumina, F. Hoffman-La Roche Ltd., QIAGEN, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies, PierianDx, Genomatix GmbH, DNASTAR, Inc., Perkin Elmer, Inc., Eurofins GATC Biotech GmbH, BGI, Agilent Technologies, Inc., Pacific Biosciences of California, Inc. and Twist Bioscience Corporation. The commercially relevant division is 37.97% of 2025 revenue in Consumables, where the volume is, against 20.26% growth in Data Analysis, where share moves.
Mexico
2nd-largest in Latin America, growing 4.0×.
- In region 2 of 2
- Of region 30.1%
- Of global 1.5%
- Revenue $0.22B → $0.89B
1.52% of global revenue is generated in Mexico; USD 0.22 billion in 2025, reaching USD 0.89 billion in 2034, and 30.14% of Latin America.
Middle East and Africa Market Analysis
The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 3.4×.
- Rank 5 of 5
- 2025 share 5%
- By 2034 5%
- Revenue $0.73B → $2.45B
USD 0.73 billion of 2025 revenue is generated in Middle East and Africa, 5.03% of the global next generation sequencing market on the way to USD 2.45 billion by 2034. Among the five regions it ranks fifth by revenue in both years.
4.99% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.
Segment composition follows the global pattern: Consumables largest at 37.97% of 2025 revenue, Data Analysis fastest at 20.26%. Middle East and Africa is reported axis by axis and country by country in the full study.
Saudi Arabia
The largest market in Middle East and Africa, growing 3.3×.
- In region 1 of 2
- Of region 35.6%
- Of global 1.8%
- Revenue $0.26B → $0.86B
35.62% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.26 billion, rising to USD 0.86 billion by 2034. 35.62% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 0.73 billion in 2025 and USD 2.45 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
The product pattern in Saudi Arabia is the global one: 37.97% of 2025 revenue in Consumables, 34% by 2034, against 20.26% growth in Data Analysis taking it from 13.99% to 22%. Since 35.62% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Per-product revenue for Saudi Arabia appears on its own in the full report.
In Saudi Arabia, next generation sequencing systems intended for clinical use are regulated by the Saudi Food and Drug Authority as medical devices, requiring listing on the Medical Devices National Registry and demonstration of conformity with internationally recognised standards for in vitro diagnostic performance and quality management. A locally licensed authorized representative must hold the registration on the manufacturer's behalf and take responsibility for post-market surveillance and incident reporting within the Kingdom. Labelling must appear in Arabic alongside the source language, and any laboratory offering sequencing-based testing operates under separate healthcare-facility licensing overseen by the health ministry, in addition to the device-level registration held by the supplier.
In Saudi Arabia the field is Illumina, F. Hoffman-La Roche Ltd., QIAGEN, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies, PierianDx, Genomatix GmbH, DNASTAR, Inc., Perkin Elmer, Inc., Eurofins GATC Biotech GmbH, BGI, Agilent Technologies, Inc., Pacific Biosciences of California, Inc. and Twist Bioscience Corporation. Volume sits in Consumables at 37.97% of 2025 revenue; movement sits in Data Analysis at 20.26% growth.
South Africa
2nd-largest in Middle East and Africa, growing 3.4×.
- In region 2 of 2
- Of region 24.7%
- Of global 1.2%
- Revenue $0.18B → $0.61B
South Africa is sized at USD 0.18 billion in 2025, rising to USD 0.61 billion by 2034; 1.24% of global revenue and 24.66% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product, Technology, Application, Workflow, End User, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Suppliers Compete on Consumables Volume and Data Analysis Momentum
The suppliers covered are: Illumina, F. Hoffman-La Roche Ltd., QIAGEN, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies, PierianDx, Genomatix GmbH, DNASTAR, Inc., Perkin Elmer, Inc., Eurofins GATC Biotech GmbH, BGI, Agilent Technologies, Inc., Pacific Biosciences of California, Inc. and Twist Bioscience Corporation.
The product axis, not the regional one, is where competition happens. Consumables is 37.97% of 2025 revenue at USD 5.51 billion and still 34% in 2034, so it is where the volume sits and where an incumbent's position is hardest to move. Data Analysis, compounding at 20.26% against 11.96% for Platforms, is where share changes hands over the forecast period. Holding the first and taking the second are separate capabilities, which is why a market of USD 14.51 billion supports as many suppliers as it does.
Competition in this market centers on sequencing chemistry and read-accuracy performance, breadth of instrument portfolio across throughput tiers, and regulatory clearance experience for companion diagnostics and clinical assays, since those clearances take years to accumulate and are difficult for a newer entrant to match quickly. The largest suppliers combine platform, reagent and data analysis software into one ecosystem and hold the deepest distribution and service networks, which matters for placing instruments in hospital and reference laboratories. Smaller and regional suppliers compete on price in consumables and library preparation kits, on niche workflow specialization such as long-read sequencing, or on local distribution relationships in markets the largest suppliers serve indirectly.
Geographic reach is the other axis of competition. North America alone accounts for 41.97% of 2025 revenue, so a supplier absent there is absent from the largest part of the market whatever its position elsewhere; Europe adds a further 25.98%.
Company-level profiles, financials, shares and development histories are part of the full report rather than this summary.
List of Key Next Generation Sequencing Market Companies Profiled
15 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Illumina(United States)
- F. Hoffman-La Roche Ltd.(Switzerland)
- QIAGEN(Netherlands)
- Thermo Fisher Scientific, Inc.(United States)
- Bio-Rad Laboratories, Inc.(United States)
- Oxford Nanopore Technologies(United Kingdom)
- PierianDx(United States)
- Genomatix GmbH(Germany)
- DNASTAR, Inc.(United States)
- Perkin Elmer, Inc.(United States)
- Eurofins GATC Biotech GmbH(Germany)
- BGI(China)
- Agilent Technologies, Inc.(United States)
- Pacific Biosciences of California, Inc.(United States)
- Twist Bioscience Corporation(United States)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Product, Technology, Application, Workflow, End User), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 15 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Next Generation Sequencing Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Next Generation Sequencing Market Overview, By Product, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Next Generation Sequencing Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Next Generation Sequencing Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Next Generation Sequencing Market Overview, By Workflow, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Next Generation Sequencing Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Next Generation Sequencing Market Size — Segment Comparison
Chapter 22.Global Next Generation Sequencing Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Next Generation Sequencing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Next Generation Sequencing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Next Generation Sequencing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Next Generation Sequencing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Next Generation Sequencing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Product
6- 01Consumables
- 02Platforms
- 03Data Analysis
- 04Sample preparation
- 05Target Enrichment
- 06Others
By Technology
4- 01WGS
- 02Whole Exome Sequencing
- 03DNA-based
- 04RNA-based
By Application
23- 01Oncology
- 02Diagnostics and Screening
- 03Oncology Screening
- 04Sporadic Cancer
- 05Inherited Cancer
- 06Companion Diagnostics
- 07Other Diagnostics
- 08Clinical Investigation
- 09Infectious Diseases
- 10Inherited Diseases
- 11Idiopathic Diseases
- 12Non-communicable/Other Diseases
- 13NIPT
- 14Aneuploidy
- 15Microdeletions
- 16PGT
- 17Newborn Genetic Screening
- 18Single Gene Analysis
- 19HLA Typing/Immune System Monitoring
- 20Metagenomics
- 21Epidemiology & Drug Development
- 22Agrigenomics & Forensics
- 23Consumer Genomics
By Workflow
8- 01NGS Library Preparation Kits
- 02Semi-automated Library Preparation
- 03Automated Library Preparation
- 04Clonal Amplification
- 05NGS Data Analysis
- 06NGS Primary Data Analysis
- 07NGS Secondary Data Analysis
- 08NGS Tertiary Data Analysis
By End User
4- 01Academic & Research Institutes
- 02Hospitals & Clinics
- 03Pharmaceutical & Biotechnology Companies
- 04Others
Segment categories shown for scope reference. See the Summary tab for revenue share by By Product. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The estimate is built upward from sequencing volumes: instrument shipments and installed-base run rates by platform type, consumable and reagent kit sales per run, and library preparation and target enrichment kit attach rates, each priced at realised list and discounted transaction levels rather than list price alone. Data analysis revenue is built separately from software licensing and per-sample bioinformatics service fees. This bottom-up build is then checked against disclosed revenue from the platform manufacturers and reagent suppliers named in this report, segmented by their own reported sequencing and consumables lines where they disclose that detail. Where the two diverge, the correction is made to the underlying bottom-up assumption, typically a unit price or an attach rate, rather than by averaging the two figures together.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interviews target genomics core facility directors and procurement leads at academic and hospital sequencing centers, commercial and product managers at platform and reagent suppliers, and regulatory affairs contacts at companies pursuing companion diagnostics clearances, since these roles set purchase volume, pricing and adoption timing respectively. Distributor and channel partner contacts are also included in regions where direct sales are less common. Sampling emphasises the United States and Western Europe, where sequencing capacity and public disclosure are both concentrated, with additional outreach into China, Japan and India to capture the platform and consumables demand building in Asia Pacific. Findings from these conversations are used to test the bottom-up volume and price assumptions described above.
Desk research draws on FDA 510(k) and CE-IVD clearance listings for sequencing platforms and companion diagnostics assays, published customs and trade codes covering sequencing instruments and reagent kits, and national genomics program disclosures such as funding and testing volumes reported by public health genomics initiatives. Platform and reagent supplier annual reports and investor disclosures are read for segment-level revenue where provided. Academic core facility procurement records and public tenders are used where available to cross-check instrument placement counts by region. Patent filings around library preparation and target enrichment chemistries are reviewed to track which suppliers are active in each workflow step.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from expected declines in per-sample sequencing cost, the pace at which companion diagnostics and reproductive health screening protocols move from specialist centers into routine clinical use, and the rate at which academic and hospital sequencing capacity expands in Asia Pacific. Reagent and consumables pricing is assumed to soften gradually as competition among suppliers increases, rather than staying flat. The forecast normalizes for pandemic-era funding surges that inflated public sequencing volumes in the early historical years, treating that period as elevated rather than as the new baseline. For the forecast to hold, clinical reimbursement pathways for companion diagnostics and NIPT need to keep expanding at broadly their current pace.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs are back-tested against recorded platform shipment and reagent revenue growth for 2020 through 2024 to confirm the bottom-up build reproduces already-known historical trends before it is extended into the forecast. Segment share shifts, particularly the move toward data analysis and away from hardware as a share of total spend, are reviewed against the roles described in primary research to confirm the direction and rough pace are consistent with what buyers describe. Sensitivities are tested on the two assumptions the model is most exposed to: sequencing cost decline pace and companion diagnostics adoption speed, each flexed independently to see how far the base case forecast could move.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is firmest for platform and consumables revenue in the United States and Western Europe, where supplier disclosure is most complete, and weakest for country-level detail in Latin America and Middle East and Africa, where public reporting is thin and the estimate leans more on adjacent-market analogues. Application-level detail within reproductive health screening and consumer genomics is similarly softer, since adoption reporting at that level of granularity is inconsistent across countries. A material shift in reimbursement policy for companion diagnostics or NIPT in a major market would be the most likely trigger for a future revision of these figures.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Next Generation Sequencing Market projected to reach?
USD 49.09 Billion by 2034, CAGR 14.5%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 41.97% of global revenue through 2034.
05Which segment leads the market?
Consumables is the largest line by Product, at 37.97% of revenue in 2025.
06Who are the key companies profiled?
Illumina, F. Hoffman-La Roche Ltd., QIAGEN, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies, PierianDx, Genomatix GmbH, DNASTAR, Inc., Perkin Elmer, Inc., Eurofins GATC Biotech GmbH, BGI, Agilent Technologies, Inc., Pacific Biosciences of California, Inc., Twist Bioscience Corporation. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.